Deciphera Competitors

Delisted . USA . 
Stock . Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals competes with ANI Pharmaceuticals, Phibro Animal, Prestige Brand, Evotec SE, and Supernus Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Deciphera Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Deciphera Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Deciphera Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Deciphera Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Deciphera Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Deciphera and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Deciphera Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PBH
+ 0.77
PAHC
ALKS
+ 0.77
PBH
NBIX
+ 0.69
SUPN
COLL
+ 0.65
SUPN
IRWD
+ 0.64
NBIX
ALKS
+ 0.63
PAHC
  
High negative correlations   
ALKS
- 0.85
IRWD
NBIX
- 0.79
PBH
ALKS
- 0.72
NBIX
IRWD
- 0.71
PBH
IRWD
- 0.65
ANIP
IRWD
- 0.59
PAHC

Risk-Adjusted Indicators

There is a big difference between Deciphera Stock performing well and Deciphera Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Deciphera Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EGRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ANIP  1.67  0.31  0.15  0.16  1.93 
(1.83)
 3.04 
(3.49)
 18.94 
PAHC  2.11  0.06  0.00 (0.10) 0.00 
 0.00 
 3.84 
(5.81)
 17.08 
PBH  1.33  0.06  0.00 (0.05) 0.00 
 0.00 
 2.22 
(2.43)
 17.56 
EVO  2.57 (0.36) 0.00 (0.71) 0.00 
 0.00 
 4.45 
(6.10)
 19.07 
SUPN  1.51 (0.16) 0.00 (0.46) 0.00 
 0.00 
 2.40 
(2.63)
 22.74 
COLL  1.78  0.03  0.00 (0.05) 0.00 
 0.00 
 3.47 
(3.02)
 18.67 
NBIX  1.48 (0.13) 0.00 (0.42) 0.00 
 0.00 
 2.19 
(3.11)
 23.54 
IRWD  4.13 (0.71) 0.00 (0.60) 0.00 
 0.00 
 6.21 
(10.26)
 54.21 
ALKS  1.33  0.18  0.18  0.29  1.32 
(1.54)
 3.78 
(2.44)
 10.24 
All Fundamental Data

Deciphera Pharmaceuticals Competitive Analysis

The better you understand Deciphera Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Deciphera Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Deciphera Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ANIP PAHC PBH EVO SUPN COLL NBIX IRWD ALKS AVDL
 1.68 
 62.49 
ANI
 3.71 
 21.25 
Phibro
 1.04 
 83.69 
Prestige
 3.54 
 3.51 
Evotec
 0.29 
 31.26 
Supernus
 1.24 
 29.46 
Collegium
 1.61 
 110.75 
Neurocrine
 1.32 
 1.49 
Ironwood
 1.22 
 34.03 
Alkermes
 0.72 
 8.33 
Avadel
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Relatively risky
Very steady
Very steady
Very steady
Very risky
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Modest
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Very Low
Below Average
Very Low
Below Average
Very Low
Quite High
Very Small
Below Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Hold
Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Strong Hold
Buy
Hold
Strong Hold
Strong Hold
Strong Hold
Cautious Hold
Strong Buy
Strong Hold
Current Ratio
3.35
2.97
2.09
3.21
0.85
0.99
2.48
26.52
2.38
2.72
Net Asset
1.28 B
982.18 M
3.32 B
2.25 B
1.37 B
1.66 B
3.72 B
471.07 M
2.06 B
164.24 M
Profit Margin
-0.0302
0.0175
0.19
-0.22
0.11
0.11
0.14
0.0052
0.24
-1.12
EBITDA
63.12 M
84.61 M
373.86 M
24.12 M
178.28 M
169.9 M
610.1 M
94.85 M
420.64 M
(35.57 M)
Operating Margin
0.008
0.12
0.32
-0.18
0.11
0.24
0.21
0.37
0.38
-0.31
Current Valuation
1.87 B
1.62 B
5.08 B
1.3 B
1.33 B
1.61 B
10.25 B
752.56 M
4.76 B
738.65 M
Price To Book
3.41
3.62
2.3
1.16
1.69
4.0
4.2
2.59
3.71
10.98
Retained Earnings
(100.28 M)
243.89 M
1.34 B
(476.29 M)
556.43 M
(164 M)
29.2 M
(1.7 B)
(976.46 M)
(794.33 M)
Current Asset
192.58 M
342.83 M
249.01 M
N/A
105.95 M
96.88 M
384.07 M
500.2 M
754.96 M
177.85 M
Five Year Return
N/A
1.85
N/A
4.88
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.63
0.58
0.46
0.96
0.84
0.99
0.35
0.37
0.58
1.63
Number Of Employees
897
1.94 K
570
5.01 K
674
357
1.8 K
N/A
1.8 K
188
Shares Outstanding
21.76 M
20.34 M
49.54 M
355.11 M
55.81 M
31.49 M
99.7 M
160.03 M
162.61 M
96.27 M
Cash Flow From Operations
64.02 M
87.59 M
248.93 M
36.44 M
171.95 M
204.98 M
595.4 M
183.43 M
439.12 M
(46.91 M)
Annual Yield
N/A
0.0218
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
314.98 M
525.46 M
1.14 B
626.2 M
34.27 M
859.3 M
455.1 M
715.54 M
75.54 M
1.7 M
Return On Equity
-0.0418
0.0746
0.13
-0.16
0.0755
0.33
0.14
-5.75
0.28
-1.0
Return On Asset
0.0084
0.056
0.0619
-0.0177
0.029
0.0889
0.1
0.15
0.13
-0.34
Number Of Shares Shorted
2.56 M
870.53 K
1.52 M
689.52 K
5.72 M
5.21 M
3.04 M
10.7 M
11.57 M
10.35 M
Book Value Per Share
20.54
6.09
36.08
5.46
18.58
7.28
26.05
-1.89
9.03
0.98
Current Liabilities
11.76 M
108.78 M
106.68 M
N/A
56.93 M
8.43 M
25.71 M
76.47 M
236.21 M
59.19 M
Total Asset
1.28 B
982.18 M
3.32 B
2.25 B
1.37 B
1.66 B
3.72 B
471.07 M
2.06 B
164.24 M
Debt To Equity
0.86
1.79
0.95
0.4
0.53
3.82
0.18
0.78
0.38
2.63
Short Ratio
11.31
3.22
4.49
13.14
10.08
16.56
2.02
2.59
7.5
12.45
Target Price
81.71
21.0
89.14
7.09
38.8
42.8
164.37
8.67
37.8
24.7
Last Dividend Paid
N/A
0.48
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
98.58
99.41
99.0
2.52
94.84
98.07
97.8
98.2
98.56
80.0
Market Capitalization
1.34 B
829.92 M
4.1 B
1.2 B
1.74 B
916.23 M
10.87 B
241.64 M
5.47 B
1.27 B
Price To Earning
43.35
11.39
18.23
444.0
15.25
28.8
202.9
18.35
-38.45
61.46
Price To Earnings To Growth
1.06
1.66
2.75
3.15
1.47
N/A
0.27
-0.26
-1057.29
0.07
Price To Sales
2.18
0.75
3.67
1.55
2.63
1.45
4.61
0.69
3.51
4.79
Net Income
(18.52 M)
2.42 M
209.34 M
(83.91 M)
73.86 M
69.19 M
341.3 M
(1 B)
367.07 M
(48.83 M)
Earnings Per Share
-1.04
0.48
4.26
-0.53
1.32
1.86
3.29
0.01
2.2
-1.09
Shares Owned By Insiders
11.38
0.59
1.0
N/A
5.16
1.93
1.02
1.8
1.44
4.77
Revenue
614.38 M
1.02 B
1.13 B
781.43 M
661.82 M
631.45 M
2.36 B
351.41 M
1.56 B
169.12 M
Working Capital
334 M
396.85 M
258 M
438.59 M
393.67 M
(27.25 M)
1.22 B
(42.81 M)
950.16 M
85.37 M
Cash And Equivalents
63.38 M
98.67 M
58.49 M
823.67 M
360.79 M
122.72 M
799.4 M
504.36 M
580.97 M
104.12 M
Cash Per Share
3.89
2.44
0.72
2.33
6.74
3.6
8.31
3.29
3.54
1.74
Gross Profit
364.17 M
353.96 M
625.12 M
106.45 M
583.91 M
547.92 M
1.59 B
241.46 M
1.31 B
16.59 M
Day Typical Price
62.52
21.14
83.39
3.5
31.23
29.49
110.02
1.5
33.92
8.37
Accumulation Distribution
6643.63
10345.69
3663.76
2176.25
0.0029
12950.62
31160.78
128615.0
70279.32
16787.14
Market Facilitation Index
0.0
0.0
0.0
0.0
0.09
0.0
0.0
N/A
0.0
N/A
Daily Balance Of Power
0.4858
1.151515
0.7227
1.714286
1.0
0.36
0.5432
(0.25)
0.3361
(0.30)
Period Momentum Indicator
1.03
0.76
0.86
0.12
0.09
0.36
1.76
(0.02)
0.41
(0.06)
Rate Of Daily Change
1.02
1.04
1.01
1.04
1.0
1.01
1.02
0.99
1.01
0.99
Day Median Price
62.54
21.08
83.24
3.5
31.22
29.51
109.65
1.51
33.87
8.39
Price Action Indicator
0.47
0.55
0.88
0.075
0.09
0.13
1.98
(0.03)
0.37
(0.09)
Coefficient Of Variation
1480.65
(2,848)
(8,710)
(812.65)
(1,147)
(38,674)
(1,520)
(740.43)
1426.77
(2,769)
Mean Deviation
1.67
2.11
1.33
2.57
1.51
1.78
1.48
4.13
1.33
2.54
Jensen Alpha
0.3076
0.0583
0.0607
(0.36)
(0.16)
0.027
(0.13)
(0.71)
0.1794
(0)
Total Risk Alpha
0.5929
0.4172
0.3522
0.1509
0.1992
0.4267
0.2754
0.2197
0.4343
0.5619
Sortino Ratio
0.1451
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.184
N/A
Downside Variance
4.41
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2.04
N/A
Standard Deviation
2.55
3.2
2.31
3.54
2.57
2.63
2.78
6.87
1.86
4.32
Kurtosis
10.29
2.84
25.9
2.07
20.2
12.85
29.37
13.26
3.41
20.18
Potential Upside
3.04
3.84
2.22
4.45
2.4
3.47
2.19
6.21
3.78
5.12
Treynor Ratio
0.1593
(0.1)
(0.05)
(0.71)
(0.46)
(0.05)
(0.42)
(0.60)
0.2913
(0.15)
Maximum Drawdown
18.94
17.08
17.56
19.07
22.74
18.67
23.54
54.21
10.24
31.3
Variance
6.52
10.26
5.32
12.53
6.62
6.93
7.72
47.13
3.47
18.66
Market Risk Adjusted Performance
0.1693
(0.09)
(0.04)
(0.70)
(0.45)
(0.04)
(0.41)
(0.59)
0.3013
(0.14)
Risk Adjusted Performance
0.0637
(0.02)
(0)
(0.1)
(0.07)
0.0046
(0.05)
(0.11)
0.0646
(0.02)
Skewness
1.92
0.7321
4.12
0.4554
(3.06)
2.61
(4.43)
(2.18)
1.38
(3.00)
Semi Deviation
1.93
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.32
N/A
Information Ratio
0.1193
0.0062
0.0459
(0.09)
(0.04)
0.0477
(0.02)
(0.12)
0.1411
(0.01)
Value At Risk
(3.49)
(5.81)
(2.43)
(6.10)
(2.63)
(3.02)
(3.11)
(10.26)
(2.44)
(4.23)
Expected Short fall
(1.83)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(1.54)
N/A
Downside Deviation
2.1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.43
N/A
Semi Variance
3.73
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.74
N/A

Deciphera Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Deciphera Pharmaceuticals Competition

Deciphera Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Deciphera Pharmaceuticals in relation to its competition. Deciphera Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Deciphera Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Deciphera Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Deciphera Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Deciphera Pharmaceuticals position

In addition to having Deciphera Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Music and Video Thematic Idea Now

Music and Video
Music and Video Theme
Companies specializing in music, video and movie production and distribution. The Music and Video theme has 31 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Music and Video Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Consideration for investing in Deciphera Stock

If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Transaction History
View history of all your transactions and understand their impact on performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY